Skip to main content
. 2020 Jul 28;12(8):2091. doi: 10.3390/cancers12082091

Figure 5.

Figure 5

PRMT5 inhibitor treatment is shown to affect apoptosis in the KRAS mutant CRC cells by Annexin V analysis. (a) Flow cytometry dot plots displaying Annexin V assay results; (b) Quantified Annexin V assay results displaying that PRMT5 inhibitor treatment shows an 8.0% (p < 0.05) greater increase in apoptosis after 60 h of 10 µM PRMT5 inhibitor treatment in the KRAS mutant CRC cells when compared to the KRAS WT CRC cells. Data are expressed as means + SD from three independent experiments using four CRC cell lines (2 KRAS mutant, 2 KRAS WT). Data for the individual cell lines can be seen in Figures S2 and S3. * represents p < 0.05.